$ELAN

O'Neill Shiv purchased $94K of ELAN

O'Neill Shiv (GC AND CORP SEC) purchased 3,998 shares of Elanco Animal Health Inc (ELAN) at $23.58 on 2026-08-18.

Original reporting
SEC EDGAR · O'Neill Shiv
Published Aug 18, 2026, 8:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 9:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ELAN
Bullish
medium confidence
Mentioned
$ELAN
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELANBullishLow
01

Why it matters

The only new fact is the insider’s purchase details (shares, price, total value, and post-transaction holdings). There is no accompanying company guidance, operational update, or regulatory/legal development.

02

Market read

Traders may note the insider buy as a mild sentiment input, but it is unlikely to drive a durable repricing without additional company-specific catalysts.

03

What to watch

The filing does not state a 10b5-1 plan and provides no context on motivation, timing, or whether the insider has ongoing trading patterns.

Relevance 4/10Novelty 3/10Timing: filed on 2026-08-18, after-hours SEC EDGAR timestamp

Background

This is an SEC Form 4 insider transaction disclosure for Elanco Animal Health Inc.

Company-level read

Ticker impact

$ELANBullishMedium confidence
Context

Elanco Animal Health insider O'Neill Shiv filed a Form 4 open-market purchase of 3,998 shares at $23.58 on 2026-08-18.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically small for routine Form 4 buys.

Evidence & confidence

Form 4 insider purchases can be read as confidence, but the article provides no new operational or financial information, and the transaction is not described as part of a major event or 10b5-1 plan.

Market effects

No sector-wide read-through is provided beyond a single insider transaction.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be routine liquidity or diversification activity and may not reflect a new fundamental outlook.

Key entities

  • Elanco Animal Health Inc

    Subject of the Form 4 insider transaction disclosure.

  • O'Neill Shiv

    Reported officer (GC and Corp SEC) who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ELANMed

Elanco rating upgraded by Fitch on deleveraging progress

Fitch Ratings upgraded Elanco Animal Health’s (NYSE:ELAN) Long-Term Issuer Default Rating to BB+ from BB and raised senior secured to BBB- from BB+ and senior unsecured to BB+ from BB, with a stable outlook. Fitch cited balance-sheet deleveraging, share gains, and cash flow. It projects EBITDA leverage below 3.5x, debt down about $650M since 2024, and free cash flow rising from $345M (2026) to ~$575M (2028).

$ELANHighAI 9/10

Elanco (ELAN) Q2 2026 Earnings Call Transcript

Elanco Animal Health (ELAN) reported Q2 2026 revenue of $1.368B, up 8% organic constant currency, and adjusted EBITDA of $288M (+21%). Adjusted EPS was $0.34 (+31%). Management raised 2026 revenue guidance to $5.09B-$5.14B and adjusted EPS to $1.10-$1.16, citing innovation sales led by Zenrelia and Credelio Quattro.

$ELANHighAI 8/10

ELAN Stock Jumps As Earnings Beat Fuels Bullish Guidance

Elanco Animal Health (NYSE: ELAN) shares rose about 3.4% after Q2 2026 results beat expectations and management raised guidance. Elanco reported revenue of $1.37B vs $1.31B expected and adjusted EPS of $0.34 vs $0.27, with 2026 guidance of EPS $1.10–$1.16 and revenue $5.09B–$5.14B. Analysts including KeyBanc, UBS and Citi raised targets to $30–$34.

$ELANMedAI 8/10

Elanco Animal Health Q2 Earnings Call Highlights

Elanco Animal Health (NYSE:ELAN) reported Q2 updates on pet and farm results. Credelio Quattro gained market share, with product in over half of U.S. clinics. Early Befrena demand was described as soft-launched in May, with supply constrained until early 2027. AdTab international OTC parasiticides sales rose over 30%. Elanco raised 2026 innovation revenue target to about $1.25B and guided FY revenue $5.09B-$5.14B, adjusted EBITDA $1.01B-$1.035B, adjusted EPS $1.10-$1.16.

$ELANMedAI 8/10

Elanco Animal Health Boosts FY26 Outlook; Stock Up 7% - Update

Elanco Animal Health (ELAN) reported Q2 results and issued Q3 guidance, expecting adjusted EPS of $0.19 to $0.22 on revenue of $1.195B to $1.220B, with 5% to 7% organic constant-currency growth. For FY2026, it raised outlook to adjusted EPS $1.10 to $1.16 on revenue $5.09B to $5.14B, up from prior $1.03 to $1.09 on $5.01B to $5.085B. Shares rose to $27.37.